StockIQpro
NASDAQ:CRDF

Cardiff Oncology, Inc.

Track all markets on TradingView
Track all markets on TradingView

Cardiff Oncology, Inc.'s revenue fell 13.2% in fiscal 2025 to $593,000 while operating margin fell to −8256.3%. Free cash flow was −$38.0M, −6402.5% of revenue, and the diluted share count rose 40.3%.Summary generated from Cardiff Oncology, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$593,000
Revenue growth−13.2%
Revenue, 5-yr CAGR+10.1%
Gross marginn/a
Operating margin−8256.3%
Net margin−7732.0%
ROICn/a
Return on equity−71.5%
Debt / equityn/a
Free cash flow−$38.0M
FCF margin−6402.5%
Share count change+40.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue00011
Operating income−29−40−45−49−49
Net income−28−39−41−45−46
Free cash flow−23−35−31−38−38

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)